La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Bolt Biotherapeutics Dividendo

Dividendo criteri di controllo 0/6

Bolt Biotherapeutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	1.9%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$1.73
Previsione del rendimento del dividendo	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

May 21

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Mar 15

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Dec 01

Bolt Biotherapeutics: A Promised Follow Up

Aug 26

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

Aug 10

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di BOLT siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di BOLT siano aumentati.

Rendimento dei dividendi rispetto al mercato

Bolt Biotherapeutics Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di BOLT rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (BOLT)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.3%
Media del settore (Biotechs)	1.9%
Analista previsionale (BOLT) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di BOLT rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di BOLT rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di BOLT per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché BOLT non ha segnalato alcun pagamento.

Bolt Biotherapeutics Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors

Consensus EPS estimates fall by 13%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Pomerantz Law Firm Announces the Filing of A Class Action Against Bolt Biotherapeutics, Inc. and Certain Officers - BOLT

High number of new directors

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

Consensus revenue estimates decrease by 12%, EPS upgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bolt Biotherapeutics, Inc., Annual General Meeting, Jun 12, 2024

Consensus revenue estimates increase by 44%, EPS downgraded

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Price target increased by 9.4% to US$5.25

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu

Consensus revenue estimates increase by 21%

Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Price target decreased by 7.7% to US$4.80

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Bolt Biotherapeutics, Inc. Appoints Laura Berner to Board of Directors

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$6.40

Bolt Biotherapeutics: A Promised Follow Up

Consensus revenue estimates increase by 36%

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 2500 Index

Price target decreased to US$11.50

High number of new directors

We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bolt Biotherapeutics, Inc. Announces Resignation of David Dornan as Chief Scientific Officer, Effective from March 11, 2022

Price target decreased to US$13.67

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

Less than half of directors are independent

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth

Consensus revenue estimates fall to US$1.00m

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 3000E Growth Index

Bolt Biotherapeutics, Inc. announced that it has received $15 million in funding from Genmab A/S

Bolt Biotherapeutics, Inc. Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

Bolt Biotherapeutics, Inc. announced that it expects to receive $15 million in funding from Genmab A/S

Full year 2020 earnings released: US$28.89 loss per share (vs US$15.29 loss in FY 2019)

Bolt Biotherapeutics, Inc. has completed an IPO in the amount of $230 million.

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti